; and (II) does not include— (aa) intermediates used in the synthesis of a drug product; or (bb) components that may undergo chemical change in the manufacture of a drug product and be present in a drug product in a modified form that is intended to furnish such activity or effect. (ii) Agreement on subsidies and countervailing measures The term Agreement on Subsidies and Countervailing Measures means the agreement referred to in section 101(d)(12) of the Uruguay Round Agreements Act ( 19 U.S.C. 3511(d)(12) ). (iii) Antidumping agreement The term Antidumping Agreement means the Agreement on Implementation of Article VI of the General Agreement on Tariffs and Trade 1994 referred to in section 101(d)(7) of the Uruguay Round Agreements Act ( 19 U.S.C. 3511(d)(7) ). (iv) Biological product The term biological product has the meaning given to such term in section 351(i) of the Public Health Service Act ( 42 U.S.C. 262(i) ). (v) Covered pharmaceutical product The term covered pharmaceutical product means— (I) a drug (including a biological product); or (II) an active pharmaceutical ingredient. . 305. Reauthorization of trade agreements authority Section 103 of the Bipartisan Congressional Trade Priorities and Accountability Act of 2015 ( 19 U.S.C. 4202 ) is amended— (1) in subsection (a)— (A) by striking July 1, 2018 each place it appears and inserting July 1, 2023 ; and (B) by striking July 1, 2021 each place it appears and inserting July 1, 2026 ; (2) in subsection (b)— (A) by striking July 1, 2018 each place it appears and inserting July 1, 2023 ; and (B) by striking July 1, 2021 each place it appears and inserting July 1, 2026 ; and (3) in subsection (c)— (A) by striking July 1, 2018 each place it appears and inserting July 1, 2023 ; (B) by striking June 30, 2018 and inserting June 30, 2023 ; (C) in paragraph (1)(B), by striking July 1, 2021 and inserting July 1, 2026 ; (D) in paragraph (2), by striking April 1, 2018 and inserting April 1, 2023